SCH772984 HCl: Selective ERK1/2 Inhibitor for MAPK Pathway Research

Executive Summary: SCH772984 HCl (SKU: B5866) is a potent and selective extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor, targeting the mitogen-activated protein kinase (MAPK) signaling pathway with nanomolar potency (IC50: 4 nM for ERK1, 1 nM for ERK2) under in vitro conditions [ApexBio]. It effectively blocks ERK substrate phosphorylation (e.g., p90 ribosomal S6 kinase) and reduces ERK activation loop phosphorylation, leading to significant antiproliferative effects in BRAF- and RAS-mutant cell lines [Stern et al., 2024]. In vivo, SCH772984 HCl induces dose-dependent regression (up to 98%) of LOX BRAF V600E tumors in female nude mice, supporting its translational relevance. The compound is highly soluble in water (≥23.5 mg/mL, gentle warming) and DMSO (≥16.27 mg/mL), but insoluble in ethanol; it is stored at -20°C. Recent research links ERK pathway modulation to telomerase (TERT) regulation and DNA repair, expanding the scope of SCH772984 HCl in cancer and stem cell research [Stern et al., 2024].

Biological Rationale

The MAPK/ERK signaling pathway regulates cellular proliferation, differentiation, and survival [ApexBio]. Aberrant activation of ERK1/2 is common in cancers with BRAF or RAS mutations, contributing to resistance against upstream BRAF and MEK inhibitors [See also: Mechanistic review]. SCH772984 HCl targets this resistance node by directly inhibiting ERK1/2. Recent studies indicate that ERK signaling intersects with telomerase regulation, affecting TERT expression and possibly DNA repair—broadening its utility in both oncology and stem cell research [Stern et al., 2024].

Mechanism of Action of SCH772984 HCl

SCH772984 HCl binds to the ATP-binding pocket of ERK1 and ERK2, inhibiting their kinase activity. This prevents phosphorylation of downstream substrates, including p90 ribosomal S6 kinase (RSK), and reduces ERK activation loop phosphorylation [ApexBio]. The compound exhibits high selectivity, with IC50 values of 4 nM (ERK1) and 1 nM (ERK2) measured in cell-free biochemical assays at 25°C and physiological buffers. Inhibition of ERK1/2 activity interrupts MAPK-driven cell proliferation and survival signals, particularly in cells reliant on constitutive MAPK pathway activation [Further details in comparative analysis].

Evidence & Benchmarks

• SCH772984 HCl shows IC50 of 4 nM for ERK1 and 1 nM for ERK2 (cell-free, 25°C) (ApexBio).
• Inhibits phosphorylation of ERK substrates, including p90 ribosomal S6 kinase, in cell-based assays (ApexBio).
• Demonstrates antiproliferative activity in ~88% of BRAF-mutant and 49% of RAS-mutant tumor cell lines, with EC50 <500 nM (ApexBio).
• In vivo, 50 mg/kg (i.p., BID, 14 days) yields up to 98% regression of LOX BRAF V600E tumors in female nude mice (ApexBio).
• Knockdown of ERK pathway components (e.g., with SCH772984 HCl) may intersect with TERT expression and DNA repair in stem and melanoma cells (Stern et al., 2024).

Applications, Limits & Misconceptions

SCH772984 HCl is primarily used in preclinical research to dissect MAPK pathway dependencies and resistance in BRAF- or RAS-mutant cancers. It is not approved for diagnostic or therapeutic use. The compound is also being explored for its role in telomerase and DNA repair regulation in stem cells and melanoma models [This article expands on telomerase connections].

Common Pitfalls or Misconceptions

• It is not intended for clinical, diagnostic, or therapeutic applications.
• Efficacy and selectivity are validated primarily under controlled in vitro and preclinical in vivo conditions; results may not extrapolate directly to human patients.
• SCH772984 HCl is insoluble in ethanol—DMSO or water (with gentle warming) should be used for stock solutions.
• Short-term use of prepared solutions is recommended due to potential stability issues at room temperature.
• Not all BRAF- or RAS-mutant cell lines respond equally—some exhibit intrinsic or acquired resistance.

Workflow Integration & Parameters

SCH772984 HCl (SKU: B5866) is supplied as a solid, with a molecular weight of 624.17 g/mol. For cell-based assays, dissolve in DMSO (≥16.27 mg/mL) or water (≥23.5 mg/mL, gentle warming). Store dry at -20°C. Use freshly prepared solutions for optimal activity. Typical in vitro concentrations range from 10 nM to 1 μM, with exposure times from 1 hour to 72 hours depending on endpoint. In vivo, dosing regimens such as 50 mg/kg (i.p., BID, 14 days) have demonstrated strong tumor regression in BRAF-mutant xenograft models [Product page].

Conclusion & Outlook

SCH772984 HCl is a reference ERK1/2 inhibitor for dissecting MAPK pathway mechanisms and resistance in oncology research. Its validated potency, selectivity, and in vivo efficacy support its use in translational studies, including those probing telomerase regulation and DNA repair. For deeper mechanistic insights, see how this article updates mechanistic rationale compared to prior reviews. As research advances, selective ERK1/2 inhibitors like SCH772984 HCl may illuminate new strategies for overcoming resistance in cancer and modulating stem cell fate.